FR2429021A1 - Medicaments for tumour therapy - contg. trace elements, glycine, glycerol, ascorbic acid, tetra:halo-fluorescein, EDTA and tartrate - Google Patents
Medicaments for tumour therapy - contg. trace elements, glycine, glycerol, ascorbic acid, tetra:halo-fluorescein, EDTA and tartrateInfo
- Publication number
- FR2429021A1 FR2429021A1 FR7818346A FR7818346A FR2429021A1 FR 2429021 A1 FR2429021 A1 FR 2429021A1 FR 7818346 A FR7818346 A FR 7818346A FR 7818346 A FR7818346 A FR 7818346A FR 2429021 A1 FR2429021 A1 FR 2429021A1
- Authority
- FR
- France
- Prior art keywords
- glycine
- edta
- glycerol
- ascorbic acid
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 title abstract 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 title abstract 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 title abstract 3
- 229960005070 ascorbic acid Drugs 0.000 title abstract 2
- 235000010323 ascorbic acid Nutrition 0.000 title abstract 2
- 239000011668 ascorbic acid Substances 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 title 1
- 239000004471 Glycine Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940095064 tartrate Drugs 0.000 title 1
- 235000013619 trace mineral Nutrition 0.000 title 1
- 239000011573 trace mineral Substances 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 3
- 230000007935 neutral effect Effects 0.000 abstract 3
- 229960001484 edetic acid Drugs 0.000 abstract 2
- 230000002349 favourable effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 229910052796 boron Inorganic materials 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 229910052802 copper Inorganic materials 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010016256 fatigue Diseases 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 208000024963 hair loss Diseases 0.000 abstract 1
- 230000003676 hair loss Effects 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 229910052748 manganese Inorganic materials 0.000 abstract 1
- 229910052750 molybdenum Inorganic materials 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 229910052759 nickel Inorganic materials 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 229910052720 vanadium Inorganic materials 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Aq. pharmaceutical compsns., esp. for tumour therapy, comprise (a) a mixt. of water soluble B, F, Mg, V, Mn, Fe, Co, Ni, Cu, Zn and Mo cpds. which do not ppte. with one another or with the other components of the compsn. and which provide an acid or neutral pH; (b) glycine; (c) glycerol; (d) ascorbic acid; (e) a water-soluble neutral or acid salt of a 2,4,5,7-tetrahalofluorescein; (f) a water-soluble neutral or acid salt of ethylenediaminetetracetic acid (EDTA); and (g) Na and K double tatrate. These components are formulated with H2O and opt. other carriers, diluents and/or additives. The compsns. can be used for treatment or prophylaxis of a wide range of malignant tumours. They have no harmful side-effects and, as well as causing tumour regression, they have favourable effects and, as well as causing tumour regression, they have favourable effects on nausea, osteoporosis, pain, fatigue, insomnia, anaemia, hair loss and other symptoms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7818346A FR2429021A1 (en) | 1978-06-20 | 1978-06-20 | Medicaments for tumour therapy - contg. trace elements, glycine, glycerol, ascorbic acid, tetra:halo-fluorescein, EDTA and tartrate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7818346A FR2429021A1 (en) | 1978-06-20 | 1978-06-20 | Medicaments for tumour therapy - contg. trace elements, glycine, glycerol, ascorbic acid, tetra:halo-fluorescein, EDTA and tartrate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2429021A1 true FR2429021A1 (en) | 1980-01-18 |
| FR2429021B1 FR2429021B1 (en) | 1981-06-12 |
Family
ID=9209720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR7818346A Granted FR2429021A1 (en) | 1978-06-20 | 1978-06-20 | Medicaments for tumour therapy - contg. trace elements, glycine, glycerol, ascorbic acid, tetra:halo-fluorescein, EDTA and tartrate |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2429021A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0055118A1 (en) * | 1980-12-19 | 1982-06-30 | Wallace Lysaght | Arthritis treatment |
| WO1990012563A1 (en) * | 1989-04-24 | 1990-11-01 | Board Of Regents, The University Of Texas System | Compositions and processes for improving the cosmetic appearance, growths or healing characteristics of tissue |
-
1978
- 1978-06-20 FR FR7818346A patent/FR2429021A1/en active Granted
Non-Patent Citations (1)
| Title |
|---|
| EXBK/69 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0055118A1 (en) * | 1980-12-19 | 1982-06-30 | Wallace Lysaght | Arthritis treatment |
| WO1990012563A1 (en) * | 1989-04-24 | 1990-11-01 | Board Of Regents, The University Of Texas System | Compositions and processes for improving the cosmetic appearance, growths or healing characteristics of tissue |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2429021B1 (en) | 1981-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20180046B1 (en) | Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes | |
| EP0356435A4 (en) | Anti-inflammatory compounds and compositions. | |
| CA2265547A1 (en) | Method of treating endothelial injury | |
| SG91685G (en) | Platinum-diamine complexes,a method for the preparation thereof,a method for the preparation of a medicine using such a platinum-diamine complex for the treatment of cancer,as well as a medicine thus formed | |
| JPS4994805A (en) | ||
| HUT51594A (en) | Process for production of celates and their complexes containing ortolizating functional groups, compositions containing such active substances and process for production of conjugates consisting of one complex and linked to it antibody or fragment of antibody | |
| ES419619A1 (en) | Processes and compositions for remineralization of dental enamel | |
| ATE25238T1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION OR ARTHRITIS. | |
| FR2429021A1 (en) | Medicaments for tumour therapy - contg. trace elements, glycine, glycerol, ascorbic acid, tetra:halo-fluorescein, EDTA and tartrate | |
| EP0281070A3 (en) | Pharmaceutical composition for the treatment of cancer | |
| EP0004680A3 (en) | Pharmaceutical compositions, method of inhibiting and of treating cancerous tumours, and a nonatetraenoic acid | |
| GB1520135A (en) | Rotary harrow | |
| ES8404693A1 (en) | 14-Amino-steroid derivatives, their therapeutical use and process for their preparation. | |
| ES408279A1 (en) | Process for the preparation of methylcobalamine | |
| ES2188336A1 (en) | Soluble albumin adducts with polyhydroxilated complexes (polyalcoholic) of trivalent iron, method for obtaining them and pharmaceutical and dietetic preparations that contain them. | |
| JPS51149174A (en) | A fluid treatment process | |
| JUNG et al. | The effect of Helicobacter pylori eradication of triple therapy with omeprazole, amoxicillin and clarithromycin | |
| JPS51125758A (en) | A health promoting food | |
| KR790000562B1 (en) | Method of collecting urokinase | |
| JPS5265973A (en) | Process for treating water containing phosphate and sulfate ions | |
| FR2166349A1 (en) | Difeu alkaloids - for treating diarrhoea, peptic ulcer anorexia, as a diuretic, as a sclerosing agent | |
| ES362105A1 (en) | A method for the production of less irritating compositions by puting them in contact with the human skin. (Machine-translation by Google Translate, not legally binding) | |
| ES356078A1 (en) | Method of Manufacture of Complex Compounds of Ferric Iron with Hydrogenated Dextran and of Complex Compounds of Ferric Iron with Hydrogenated Dextran and Sodium Citrate or Citric Acid. | |
| FR2439586A1 (en) | Anticancer infusion of Ecballium elaterium root - given as aq. infusion | |
| FR2150621A2 (en) | Amino-derivs of phloroglucinol - with antiarrhythmic activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |